Pular para o conteúdo

Vulnerability in Laboratory Medicine

In the ever-evolving landscape of healthcare, laboratory medicine plays a pivotal role in diagnosis and patient care. However, this critical sector is not immune to threats. Laboratories are increasingly becoming targets for various forms of vulnerabilities, from cyberattacks to operational inefficiencies. This article sheds light on these issues, providing concrete examples to illustrate the potential risks. Cybersecurity Threats One of the most pressing concerns for modern laboratories is cybersecurity. With the integration of network-connected medical devices and data-driven patient care, clinical laboratories are exposed to malicious cyber activities. A study published in The Journal of Applied Laboratory Medicine highlights that cyberattacks can lead to extended downtimes, disrupting clinical operations and impacting patient care¹. For instance, a cyberattack on a major hospital’s laboratory systems could result in the loss of sensitive patient data or even halt the processing of critical diagnostic… 

more »Vulnerability in Laboratory Medicine

Autoinjektoren mit KI bergen Risiken

Herkömmliche Autoinjektoren sollen Patienten bei der Medikamentenverabreichung unterstützen und unterstreichen die Notwendigkeit von Qualitätskontrolle, Zuverlässigkeit und Designverbesserungen. KI-Autoinjektoren, die dieses Ziel verfolgen, bringen zusätzliche Cybersicherheits- und Softwarerisiken mit sich und erfordern ein umfassendes Risikomanagement-Framework, das Standards, Tools, Schulungen und laufende Überwachung umfasst. Die Integration von KI verspricht eine Verbesserung der Funktionalität, eine Echtzeitüberwachung und erleichtert klinische Fernstudien, zeitnahe Interventionen und maßgeschneiderte medizinische Behandlungen. https://www.frontiersin.org/articles/10.3389/fmedt.2024.1331058/full?

Primeiro paciente dos EUA em ensaio de amiloidose cardíaca

O cardiologista Brendan Carry, MD, e uma equipe de médicos da Geisinger inscreveram o primeiro paciente nos EUA em um ensaio de amiloidose cardíaca. A equipe também é a primeira nos EUA a realizar a triagem para o ensaio. „Se um paciente se qualificar para o ensaio clínico, isso nos permitirá oferecer uma opção de tratamento quando ele receber um diagnóstico de amiloidose sem ter que viajar para fora da região para receber cuidados“, disse o Dr. Carry. „A Geisinger está na vanguarda da pesquisa e dos avanços tecnológicos que permitem melhores resultados para os pacientes e melhorias em sua qualidade de vida.“ A amiloidose cardíaca é causada pelo acúmulo de proteínas entre as células musculares do coração, aumentando a espessura do coração. À medida que essas proteínas se acumulam, o coração fica mais espesso e tem dificuldade em bombear o sangue. Com o tempo, à medida que o coração engrossa, desenvolve-se insuficiência cardíaca.… 

mais »Primeiro paciente dos EUA em ensaio de amiloidose cardíaca

Vacina terapêutica contra o câncer mRNA da WestGenes recebe aprovação da FDA

WestGene, ein Biotech-Unternehmen, das sich der mRNA-Technologie verschrieben hat, gibt mit der IND-Zulassung durch die FDA für seinen therapeutischen mRNA-Krebsimpfstoff WGc-043 einen historischen Meilenstein bekannt. Diese bahnbrechende Errungenschaft markiert die weltweit erste Zulassung eines therapeutischen Krebsimpfstoffs auf der Basis von EB-Virus-mRNA. Die FDA-Zulassung für WGc-043 stellt einen bedeutenden Fortschritt in der Krebsbehandlung dar und gibt Patienten mit fortgeschrittenen Krebserkrankungen, die mit dem EB-Virus in Verbindung stehen, neue Hoffnung. Das EB-Virus steht in engem Zusammenhang mit mehr als zehn bösartigen Erkrankungen, darunter Nasopharynxkarzinom (NPC), natürliches Killer-T-Zell-Lymphom (NKTL), Magenkrebs, Lungenkrebs, Leberkrebs, Speiseröhrenkrebs, Brustkrebs, Gebärmutterhalskrebs und Autoimmunerkrankungen wie Multiple Sklerose und systemischer Lupus erythematodes. Dies sind mögliche Indikationen für WGc-043. WGc-043 zeigt vielversprechende Wirksamkeit, geringe Toxizität, breite Anwendbarkeit, effiziente Skalierbarkeit und Kosteneffizienz. Mit WGc-043 wurden bereits von Prüfärzten initiierte Studien (IIT) bei NPC und NKTL abgeschlossen, und es dabei eine überlegene Sicherheit und… 

more »WestGenes mRNA-therapeutischer Krebsimpfstoff erhält FDA-Zulassung

O que torna uma campanha de saúde pública bem-sucedida

Os países com melhor desempenho em resultados de saúde pública compartilham muitos fatores que contribuem para seu sucesso. Essa é a conclusão de um novo estudo publicado em 9 de maio na revista de acesso aberto PLOS Global Public Health pela Dra. Nadia Akseer, epidemiologista-bioestatística da Johns Hopkins Bloomberg School of Public Health e coautora do estudo, e colegas do programa Exemplars in Global Health (EGH). No novo estudo, os pesquisadores analisaram sistematicamente 31 estudos anteriores do EGH em seis tópicos, incluindo mortalidade infantil abaixo de cinco anos, nanismo infantil, agentes comunitários de saúde (ACS), vacinação, resposta à COVID-19 e redução da mortalidade neonatal e materna. Os estudos incluíram dados de 19 países da África, América Latina, Ásia e Caribe. A equipe do EGH procurou temas e descobertas comuns nesses países que resultaram em sucesso programático. Em geral, os fatores que foram vistos com mais frequência em… 

mais »O que torna uma campanha de saúde pública bem-sucedida

CENTOGENE Biodatabank Cresce para Incorporar Insights de Doenças de Mais de 850.000 Pacientes Diversos

Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

Intensity Therapeutics and The Swiss Group for Clinical Cancer Research SAKK Sign Collaboration Agreement

Intensity Therapeutics, Inc. („Intensity“ or „the Company“) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK („SAKK“) to conduct a Phase 2 randomized, (one to one), controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care („SOC“) immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer („TNBC“) in 54 patients in Switzerland and selected countries in Europe (the „INVINCIBLE-4 Study“). The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial. https://www.sakk.ch/en

NeuroSigma anuncia aceitação no programa KidsX Accelerator de 2024

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) — NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program. KidsX is a global leader in pediatric digital health innovation that facilitates collaboration between leading children’s hospitals, providers, payers, investors, entrepreneurs, and corporate partners to solve the most pressing problems in pediatric care delivery. KidsX is anchored by a consortium of leading children’s hospitals in the United States and other parts of the world and leverages this unique network to help companies developing solutions for the pediatric healthcare market achieve product and business model validation. NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program

vTv Therapeutics Announces 2024 First Quarter Financial Results

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes („T1D“), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments. vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

transCampus entre TUD, Universidade de Zurique e ETH

Wie die Deutsche Forschungsgemeinschaft (DFG) am 10. Mai 2024 mitteilte, gehört das Internationale Graduiertenkolleg (IRTG) „Metabolic and Endocrine Drivers of Infection Susceptibility“ (MEDIS) der Technischen Universität Dresden (TUD), der Universität Zürich (UZH) und der Eidgenössischen Technischen Hochschule (ETH) Zürich zu den insgesamt 17 neuen DFG-Graduiertenkollegs. MEDIS-Sprecher ist Prof. Stefan Bornstein, Direktor der Medizinischen Klinik und Poliklinik III, des Zentrums für Innere Medizin Carl Gustav Carus der TUD und transCampus-Dekan. Die DFG fördert MEDIS mit rund sechs Millionen Euro, eingerichtet wird das IRTG an der Medizinischen Fakultät der TUD. Das IRTG Dresden-Zürich wird sich mit hochaktuellen Forschungshemen der metabolischen und endokrinen Einflüsse auf Infektionskrankheiten auseinandersetzen. Damit ist der Grundstein gelegt für den Aufbau eines weiteren transCampus der TUD – in diesem Fall mit der UZH und der ETH. https://tu-dresden.de/internationales/partnerschaften-kooperation/mit-wem-kooperiert-die-TUD/transcampus